INTS · Intensity Therapeutics

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

1 Enterprise Drive, Shelton, CT, 06484-4779, United States
Biotechnology
Healthcare

Market Cap

10.13M

52 Wk Range

$2.80 - $15.00

Previous Close

$3.07

Open

$2.92

Volume

21,295

Day Range

$2.59 - $2.97

Enterprise Value

1.497M

Cash

8.494M

Avg Qtr Burn

-2.50M

Insider Ownership

3.87%

Institutional Own.

27.20%

Qtr Updated

Sep 30th 2026